SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, multiple myeloma, and lupus

blonca9
Jan 15
1 min read

She describes how the company's HLA matching and CD19 relapse testing is playing out, when we can expect to see new data, and how the lupus program is progressing.

Recent Posts

See All

Talking chromatin regulation at Foghorn Therapeutics - whose partner Lilly will have preclinical data at AACR highlighting how the lead SMARCA2 program could do in combinations with other therapies

AI news: Epicrispr Biotechnologies' CEO Amber Salzman describes how her company will be utilizing AI muscle analysis in its clinical study for facioscapulohumeral muscular dystrophy

Lexeo Therapeutics' CEO Nolan Townsend highlights recent FA cardiomyopathy data and the path ahead in that indication. Plus, the latest on PKP2 ACM, and more

SF Healthcare Week: Rachel Haurwitz shares an update on Caribou Biosciences' allo CAR-T programs in NHL, multiple myeloma, and lupus

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight